A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer [clinicaltrials:NCT00220194]

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer [clinicaltrials:NCT00220194]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials:NCT00220194

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer [clinicaltrials:NCT00220194]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials:NCT00220194
Bio2RDF identifier
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00220194
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Comparing the effect of ...... ced Prostate Cancer patients.
brief title [clinicaltrials_vocabulary:brief-title]
A Six-Month, Open-Label, Cross ...... With Advanced Prostate Cancer
completion date [clinicaltrials_vocabulary:completion-date]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
official title [clinicaltrials_vocabulary:official-title]
A Six-Month, Open-Label, Cross ...... With Advanced Prostate Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
identifier
clinicaltrials:NCT00220194
title
A Six-Month, Open-Label, Cross ...... With Advanced Prostate Cancer
@en
inDataset
type
label
A Six-Month, Open-Label, Cross ...... r [clinicaltrials:NCT00220194]
@en